Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

The biotech industry is experiencing significant shifts following data readouts from the Alzheimer’s Association International Conference and recent clinical trial results. Biogen’s anti-tau therapy, daranirsen, demonstrated potential in slowing Alzheimer’s progression, while the FDA’s approval of a subcutaneous, at-home formulation of Leqembi provides a major competitive advantage in the anti-amyloid market. In the psychiatric space, Compass Pathways’ COMP360 showed efficacy in treating resistant depression, bolstered by updated FDA guidance that clarifies regulatory pathways for psychedelics. Conversely, the ATTR-CM landscape faces volatility after the late-stage failure of an AstraZeneca and Ionis antisense therapeutic, which has redirected market focus toward alternatives like BridgeBio. Additionally, Roche’s decision to terminate two Ionis-partnered Huntington’s disease programs highlights the ongoing challenges in developing effective antisense therapies for neurodegenerative conditions.